Interferon α for the Treatment of Chronic Hepatitis C in Patients Infected with Human Immunodeficiency Virus
Liver disease secondary to hepatitis C virus (HCV) infection is a rising cause of morbidity and mortality among individuals who have been infected parenterally with human immunodeficiency virus (HIV) such as injection drug users, hemophiliacs, and transfused patients. We analyzed both the efficacy o...
Gespeichert in:
| Veröffentlicht in: | Clinical infectious diseases 1996-09, Vol.23 (3), p.585-591 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 591 |
|---|---|
| container_issue | 3 |
| container_start_page | 585 |
| container_title | Clinical infectious diseases |
| container_volume | 23 |
| creator | Soriano, V. García-Samaniego, J. Bravo, R. González, J. Castro, A. Castilla, J. Martínez-Odriozola, P. Colmenero, M. Carballo, E. Suárez, D. Rodríguez-Piñero, F. J. Moreno, A. Romero, J. del Pedreira, J. González-Lahoz, J. |
| description | Liver disease secondary to hepatitis C virus (HCV) infection is a rising cause of morbidity and mortality among individuals who have been infected parenterally with human immunodeficiency virus (HIV) such as injection drug users, hemophiliacs, and transfused patients. We analyzed both the efficacy of interferon (IFN) α therapy in these patients and the predictors of response to this agent. A total of 119 patients with chronic hepatitis C (90 of whom were infected with HIV and 29 of whom were not) were included in a multicenter, prospective, open, nonrandomized observational study. IFN-α was given subcutaneously in a dosage of 5 million units three times a week during a 3-month period; those patients who responded received a dose of 3 million units given subcutaneously three times a week for an additional 9 months. One hundred seven patients completed the study; the level of aminotransferases returned to normal and sera became negative (complete response) for HCV RNA in 26 (32.5%) of 80 HIV-infected patients and 10 (37.0%) of 27 non-HIV-infected patients (P = .666) after completion of the treatment. Two variables were independently associated with a response in HIV-infected patients: a CD4+ T lymphocyte count of >500 × 106/L and a baseline HeV viremia level of |
| doi_str_mv | 10.1093/clinids/23.3.585 |
| format | Article |
| fullrecord | <record><control><sourceid>jstor_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_15853318</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>4459676</jstor_id><sourcerecordid>4459676</sourcerecordid><originalsourceid>FETCH-LOGICAL-i274t-19ab2583efe0f5d96818a23f04ec9faaff9d03146e5c8efae80b9ba567e019513</originalsourceid><addsrcrecordid>eNo90L1OwzAQwPEIgUQp7AwMHhBbWjuOE3tEFZCiig9RKGKJXOesGhKn2I6gj8WL8EwEFTH5Tv-fbnAUHRM8IljQsaqNNZUfJ3RER4yznWhAGM3jjAmy28-Y8TjllO9HB96_YkwIx2wQNVMbwGlwrUXfX0i3DoUVoLkDGRqwAbUaTVZ9NQoVsJbBBOPRBBmL7vqlFx5NrQYVoEIfJqxQ0TXSomnTdLatQBvVI7VBT8Z1_jDa07L2cPT3DqPHy4v5pIhnt1fTyfksNkmehpgIuUwYp6ABa1aJjBMuE6pxCkpoKbUWFaYkzYApDloCx0uxlCzLARPBCB1GZ9u7a9e-d-BD2RivoK6lhbbzJek_iFLCe3j6B6VXstZOWmV8uXamkW5T0gSThGU9O9myVx9a95_TlIks_83xNhsf4PM_S_dWZjnNWVk8v5TFzWJxd50_lPf0B-7whP4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>15853318</pqid></control><display><type>article</type><title>Interferon α for the Treatment of Chronic Hepatitis C in Patients Infected with Human Immunodeficiency Virus</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Jstor Complete Legacy</source><source>Oxford University Press Journals All Titles (1996-Current)</source><creator>Soriano, V. ; García-Samaniego, J. ; Bravo, R. ; González, J. ; Castro, A. ; Castilla, J. ; Martínez-Odriozola, P. ; Colmenero, M. ; Carballo, E. ; Suárez, D. ; Rodríguez-Piñero, F. J. ; Moreno, A. ; Romero, J. del ; Pedreira, J. ; González-Lahoz, J.</creator><creatorcontrib>Soriano, V. ; García-Samaniego, J. ; Bravo, R. ; González, J. ; Castro, A. ; Castilla, J. ; Martínez-Odriozola, P. ; Colmenero, M. ; Carballo, E. ; Suárez, D. ; Rodríguez-Piñero, F. J. ; Moreno, A. ; Romero, J. del ; Pedreira, J. ; González-Lahoz, J.</creatorcontrib><description>Liver disease secondary to hepatitis C virus (HCV) infection is a rising cause of morbidity and mortality among individuals who have been infected parenterally with human immunodeficiency virus (HIV) such as injection drug users, hemophiliacs, and transfused patients. We analyzed both the efficacy of interferon (IFN) α therapy in these patients and the predictors of response to this agent. A total of 119 patients with chronic hepatitis C (90 of whom were infected with HIV and 29 of whom were not) were included in a multicenter, prospective, open, nonrandomized observational study. IFN-α was given subcutaneously in a dosage of 5 million units three times a week during a 3-month period; those patients who responded received a dose of 3 million units given subcutaneously three times a week for an additional 9 months. One hundred seven patients completed the study; the level of aminotransferases returned to normal and sera became negative (complete response) for HCV RNA in 26 (32.5%) of 80 HIV-infected patients and 10 (37.0%) of 27 non-HIV-infected patients (P = .666) after completion of the treatment. Two variables were independently associated with a response in HIV-infected patients: a CD4+ T lymphocyte count of >500 × 106/L and a baseline HeV viremia level of <107 copies/mL. In the 12 months following treatment, relapses occurred in 30.8% of the HIV-infected patients and 12.5% of non-HIV-infected patients (P = .403).</description><identifier>ISSN: 1058-4838</identifier><identifier>EISSN: 1537-6591</identifier><identifier>DOI: 10.1093/clinids/23.3.585</identifier><identifier>CODEN: CIDIEL</identifier><language>eng</language><publisher>Chicago, IL: University of Chicago Press</publisher><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antiviral agents ; Biological and medical sciences ; Chronic hepatitis ; Clinical Articles ; Genotypes ; Hepacivirus ; hepatitis C virus ; HIV ; Infections ; Interferons ; Liver ; Medical sciences ; Pharmacology. Drug treatments ; RNA ; T lymphocytes ; Viremia</subject><ispartof>Clinical infectious diseases, 1996-09, Vol.23 (3), p.585-591</ispartof><rights>Copyright 1996 The University of Chicago</rights><rights>1996 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/4459676$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/4459676$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>314,778,782,801,27907,27908,58000,58233</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=3201256$$DView record in Pascal Francis$$Hfree_for_read</backlink></links><search><creatorcontrib>Soriano, V.</creatorcontrib><creatorcontrib>García-Samaniego, J.</creatorcontrib><creatorcontrib>Bravo, R.</creatorcontrib><creatorcontrib>González, J.</creatorcontrib><creatorcontrib>Castro, A.</creatorcontrib><creatorcontrib>Castilla, J.</creatorcontrib><creatorcontrib>Martínez-Odriozola, P.</creatorcontrib><creatorcontrib>Colmenero, M.</creatorcontrib><creatorcontrib>Carballo, E.</creatorcontrib><creatorcontrib>Suárez, D.</creatorcontrib><creatorcontrib>Rodríguez-Piñero, F. J.</creatorcontrib><creatorcontrib>Moreno, A.</creatorcontrib><creatorcontrib>Romero, J. del</creatorcontrib><creatorcontrib>Pedreira, J.</creatorcontrib><creatorcontrib>González-Lahoz, J.</creatorcontrib><title>Interferon α for the Treatment of Chronic Hepatitis C in Patients Infected with Human Immunodeficiency Virus</title><title>Clinical infectious diseases</title><addtitle>Clinical Infectious Diseases</addtitle><description>Liver disease secondary to hepatitis C virus (HCV) infection is a rising cause of morbidity and mortality among individuals who have been infected parenterally with human immunodeficiency virus (HIV) such as injection drug users, hemophiliacs, and transfused patients. We analyzed both the efficacy of interferon (IFN) α therapy in these patients and the predictors of response to this agent. A total of 119 patients with chronic hepatitis C (90 of whom were infected with HIV and 29 of whom were not) were included in a multicenter, prospective, open, nonrandomized observational study. IFN-α was given subcutaneously in a dosage of 5 million units three times a week during a 3-month period; those patients who responded received a dose of 3 million units given subcutaneously three times a week for an additional 9 months. One hundred seven patients completed the study; the level of aminotransferases returned to normal and sera became negative (complete response) for HCV RNA in 26 (32.5%) of 80 HIV-infected patients and 10 (37.0%) of 27 non-HIV-infected patients (P = .666) after completion of the treatment. Two variables were independently associated with a response in HIV-infected patients: a CD4+ T lymphocyte count of >500 × 106/L and a baseline HeV viremia level of <107 copies/mL. In the 12 months following treatment, relapses occurred in 30.8% of the HIV-infected patients and 12.5% of non-HIV-infected patients (P = .403).</description><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antiviral agents</subject><subject>Biological and medical sciences</subject><subject>Chronic hepatitis</subject><subject>Clinical Articles</subject><subject>Genotypes</subject><subject>Hepacivirus</subject><subject>hepatitis C virus</subject><subject>HIV</subject><subject>Infections</subject><subject>Interferons</subject><subject>Liver</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><subject>RNA</subject><subject>T lymphocytes</subject><subject>Viremia</subject><issn>1058-4838</issn><issn>1537-6591</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1996</creationdate><recordtype>article</recordtype><recordid>eNo90L1OwzAQwPEIgUQp7AwMHhBbWjuOE3tEFZCiig9RKGKJXOesGhKn2I6gj8WL8EwEFTH5Tv-fbnAUHRM8IljQsaqNNZUfJ3RER4yznWhAGM3jjAmy28-Y8TjllO9HB96_YkwIx2wQNVMbwGlwrUXfX0i3DoUVoLkDGRqwAbUaTVZ9NQoVsJbBBOPRBBmL7vqlFx5NrQYVoEIfJqxQ0TXSomnTdLatQBvVI7VBT8Z1_jDa07L2cPT3DqPHy4v5pIhnt1fTyfksNkmehpgIuUwYp6ABa1aJjBMuE6pxCkpoKbUWFaYkzYApDloCx0uxlCzLARPBCB1GZ9u7a9e-d-BD2RivoK6lhbbzJek_iFLCe3j6B6VXstZOWmV8uXamkW5T0gSThGU9O9myVx9a95_TlIks_83xNhsf4PM_S_dWZjnNWVk8v5TFzWJxd50_lPf0B-7whP4</recordid><startdate>19960901</startdate><enddate>19960901</enddate><creator>Soriano, V.</creator><creator>García-Samaniego, J.</creator><creator>Bravo, R.</creator><creator>González, J.</creator><creator>Castro, A.</creator><creator>Castilla, J.</creator><creator>Martínez-Odriozola, P.</creator><creator>Colmenero, M.</creator><creator>Carballo, E.</creator><creator>Suárez, D.</creator><creator>Rodríguez-Piñero, F. J.</creator><creator>Moreno, A.</creator><creator>Romero, J. del</creator><creator>Pedreira, J.</creator><creator>González-Lahoz, J.</creator><general>University of Chicago Press</general><scope>BSCLL</scope><scope>IQODW</scope><scope>7U9</scope><scope>H94</scope></search><sort><creationdate>19960901</creationdate><title>Interferon α for the Treatment of Chronic Hepatitis C in Patients Infected with Human Immunodeficiency Virus</title><author>Soriano, V. ; García-Samaniego, J. ; Bravo, R. ; González, J. ; Castro, A. ; Castilla, J. ; Martínez-Odriozola, P. ; Colmenero, M. ; Carballo, E. ; Suárez, D. ; Rodríguez-Piñero, F. J. ; Moreno, A. ; Romero, J. del ; Pedreira, J. ; González-Lahoz, J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-i274t-19ab2583efe0f5d96818a23f04ec9faaff9d03146e5c8efae80b9ba567e019513</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1996</creationdate><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antiviral agents</topic><topic>Biological and medical sciences</topic><topic>Chronic hepatitis</topic><topic>Clinical Articles</topic><topic>Genotypes</topic><topic>Hepacivirus</topic><topic>hepatitis C virus</topic><topic>HIV</topic><topic>Infections</topic><topic>Interferons</topic><topic>Liver</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><topic>RNA</topic><topic>T lymphocytes</topic><topic>Viremia</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Soriano, V.</creatorcontrib><creatorcontrib>García-Samaniego, J.</creatorcontrib><creatorcontrib>Bravo, R.</creatorcontrib><creatorcontrib>González, J.</creatorcontrib><creatorcontrib>Castro, A.</creatorcontrib><creatorcontrib>Castilla, J.</creatorcontrib><creatorcontrib>Martínez-Odriozola, P.</creatorcontrib><creatorcontrib>Colmenero, M.</creatorcontrib><creatorcontrib>Carballo, E.</creatorcontrib><creatorcontrib>Suárez, D.</creatorcontrib><creatorcontrib>Rodríguez-Piñero, F. J.</creatorcontrib><creatorcontrib>Moreno, A.</creatorcontrib><creatorcontrib>Romero, J. del</creatorcontrib><creatorcontrib>Pedreira, J.</creatorcontrib><creatorcontrib>González-Lahoz, J.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Clinical infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Soriano, V.</au><au>García-Samaniego, J.</au><au>Bravo, R.</au><au>González, J.</au><au>Castro, A.</au><au>Castilla, J.</au><au>Martínez-Odriozola, P.</au><au>Colmenero, M.</au><au>Carballo, E.</au><au>Suárez, D.</au><au>Rodríguez-Piñero, F. J.</au><au>Moreno, A.</au><au>Romero, J. del</au><au>Pedreira, J.</au><au>González-Lahoz, J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Interferon α for the Treatment of Chronic Hepatitis C in Patients Infected with Human Immunodeficiency Virus</atitle><jtitle>Clinical infectious diseases</jtitle><addtitle>Clinical Infectious Diseases</addtitle><date>1996-09-01</date><risdate>1996</risdate><volume>23</volume><issue>3</issue><spage>585</spage><epage>591</epage><pages>585-591</pages><issn>1058-4838</issn><eissn>1537-6591</eissn><coden>CIDIEL</coden><abstract>Liver disease secondary to hepatitis C virus (HCV) infection is a rising cause of morbidity and mortality among individuals who have been infected parenterally with human immunodeficiency virus (HIV) such as injection drug users, hemophiliacs, and transfused patients. We analyzed both the efficacy of interferon (IFN) α therapy in these patients and the predictors of response to this agent. A total of 119 patients with chronic hepatitis C (90 of whom were infected with HIV and 29 of whom were not) were included in a multicenter, prospective, open, nonrandomized observational study. IFN-α was given subcutaneously in a dosage of 5 million units three times a week during a 3-month period; those patients who responded received a dose of 3 million units given subcutaneously three times a week for an additional 9 months. One hundred seven patients completed the study; the level of aminotransferases returned to normal and sera became negative (complete response) for HCV RNA in 26 (32.5%) of 80 HIV-infected patients and 10 (37.0%) of 27 non-HIV-infected patients (P = .666) after completion of the treatment. Two variables were independently associated with a response in HIV-infected patients: a CD4+ T lymphocyte count of >500 × 106/L and a baseline HeV viremia level of <107 copies/mL. In the 12 months following treatment, relapses occurred in 30.8% of the HIV-infected patients and 12.5% of non-HIV-infected patients (P = .403).</abstract><cop>Chicago, IL</cop><pub>University of Chicago Press</pub><doi>10.1093/clinids/23.3.585</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1058-4838 |
| ispartof | Clinical infectious diseases, 1996-09, Vol.23 (3), p.585-591 |
| issn | 1058-4838 1537-6591 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_15853318 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Jstor Complete Legacy; Oxford University Press Journals All Titles (1996-Current) |
| subjects | Antibiotics. Antiinfectious agents. Antiparasitic agents Antiviral agents Biological and medical sciences Chronic hepatitis Clinical Articles Genotypes Hepacivirus hepatitis C virus HIV Infections Interferons Liver Medical sciences Pharmacology. Drug treatments RNA T lymphocytes Viremia |
| title | Interferon α for the Treatment of Chronic Hepatitis C in Patients Infected with Human Immunodeficiency Virus |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T09%3A34%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Interferon%20%CE%B1%20for%20the%20Treatment%20of%20Chronic%20Hepatitis%20C%20in%20Patients%20Infected%20with%20Human%20Immunodeficiency%20Virus&rft.jtitle=Clinical%20infectious%20diseases&rft.au=Soriano,%20V.&rft.date=1996-09-01&rft.volume=23&rft.issue=3&rft.spage=585&rft.epage=591&rft.pages=585-591&rft.issn=1058-4838&rft.eissn=1537-6591&rft.coden=CIDIEL&rft_id=info:doi/10.1093/clinids/23.3.585&rft_dat=%3Cjstor_proqu%3E4459676%3C/jstor_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=15853318&rft_id=info:pmid/&rft_jstor_id=4459676&rfr_iscdi=true |